PMID- 22519295
OWN - NLM
STAT- MEDLINE
DCOM- 20121030
LR  - 20211021
IS  - 1476-5381 (Electronic)
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 166
IP  - 5
DP  - 2012 Jul
TI  - Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging 
      opportunity to treat neurodegenerative and cerebrovascular disorders.
PG  - 1586-99
LID - 10.1111/j.1476-5381.2012.01971.x [doi]
AB  - Like type-2 diabetes mellitus (T2DM), neurodegenerative disorders and stroke are 
      an ever increasing, health, social and economic burden for developed Westernized 
      countries. Age is an important risk factor in all of these; due to the rapidly 
      increasing rise in the elderly population T2DM and neurodegenerative disorders, 
      both represent a looming threat to healthcare systems. Whereas several 
      efficacious drugs are currently available to ameliorate T2DM, effective 
      treatments to counteract pathogenic processes of neurodegenerative disorders are 
      lacking and represent a major scientific and pharmaceutical challenge. 
      Epidemiological data indicate an association between T2DM and most major 
      neurodegenerative disorders, including Alzheimer's and Parkinson's diseases. 
      Likewise, there is an association between T2DM and stroke incidence. Studies have 
      revealed that common pathophysiological features, including oxidative stress, 
      insulin resistance, abnormal protein processing and cognitive decline, occur 
      across these. Based on the presence of shared mechanisms and signalling pathways 
      in these seemingly distinct diseases, one could hypothesize that an effective 
      treatment for one disorder could prove beneficial in the others. Glucagon-like 
      peptide-1 (GLP-1)-based anti-diabetic drugs have drawn particular attention as an 
      effective new strategy to not only regulate blood glucose but also to reduce 
      apoptotic cell death of pancreatic beta cells in T2DM. Evidence supports a 
      neurotrophic and neuroprotective role of GLP-1 receptor (R) stimulation in an 
      increasing array of cellular and animal neurodegeneration models as well as in 
      neurogenesis. Herein, we review the physiological role of GLP-1 in the nervous 
      system, focused towards the potential benefit of GLP-1R stimulation as an 
      immediately translatable treatment strategy for acute and chronic neurological 
      disorders.
CI  - Published 2012. This article is a U.S. Government work and is in the public 
      domain in the USA.
FAU - Salcedo, Isidro
AU  - Salcedo I
AD  - Drug Design & Development Section, Laboratory of Neurosciences, Intramural 
      Research Program, National Institute on Aging, National Institutes of Health, 
      Baltimore, MD, USA.
FAU - Tweedie, David
AU  - Tweedie D
FAU - Li, Yazhou
AU  - Li Y
FAU - Greig, Nigel H
AU  - Greig NH
LA  - eng
GR  - Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
PT  - Review
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (GLP1R protein, human)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Receptors, Glucagon)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Animals
MH  - Brain/metabolism
MH  - Cerebrovascular Disorders/drug therapy
MH  - Glucagon-Like Peptide 1/analogs & derivatives/*pharmacology/therapeutic use
MH  - Glucagon-Like Peptide-1 Receptor
MH  - Humans
MH  - Neurodegenerative Diseases/drug therapy
MH  - Neuroprotective Agents/*pharmacology/therapeutic use
MH  - Receptors, Glucagon/*physiology
PMC - PMC3419902
EDAT- 2012/04/24 06:00
MHDA- 2012/10/31 06:00
PMCR- 2013/07/01
CRDT- 2012/04/24 06:00
PHST- 2012/04/24 06:00 [entrez]
PHST- 2012/04/24 06:00 [pubmed]
PHST- 2012/10/31 06:00 [medline]
PHST- 2013/07/01 00:00 [pmc-release]
AID - 10.1111/j.1476-5381.2012.01971.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 2012 Jul;166(5):1586-99. doi: 10.1111/j.1476-5381.2012.01971.x.